1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D4EDA550DD7CEC3F0025853C00439231
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-apac-msl-excellence-optimizing-resources-field-medical-operations-asia-pacific?opendocument
18
19opendocument
203.235.159.8
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Science Liaison

APAC MSL excellence: Optimizing resources for field medical operations in Asia-Pacific

ID: 5607


Features:

11 Info Graphics

18 Data Graphics

450+ Metrics

23 Narratives


Pages/Slides: 35


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “APAC MSL excellence: Optimizing resources for field medical operations in Asia-Pacific”


STUDY OVERVIEW

The regulatory and cultural dynamics of countries within the Asia-Pacific (APAC) region shape how pharmaceutical companies utilize their medical science liaisons (MSLs) in thought leader interactions in those countries. Likewise, organizations should consider the regional differences within each of the APAC markets while coordinating and staffing their MSL functions.

Best Practices, LLC conducted this benchmarking research to examine how leading pharmaceutical and biotechnology companies allocate critical resources (including MSL staffing levels and travel & entertainment budgets) across core markets in the APAC region. The study also assesses the utilization of MSLs during each stage of the product lifecycle.

Insights in this research are presented into following segments to illuminate field medical trends at region and country level: Europe Segment (N=58), APAC Segment (N=30), Americas Segment (N=27), MENA Segment (N=9).

KEY TOPICS

  • MSL staffing and resource levels in core global markets in APAC region
  • Travel & entertainment budgets in core global markets in the Asia-Pacific region
  • MSL new product launches support within APAC countries

KEY METRICS
  • How many brands (including both in-line and pre-launch products) does each MSL support on average in each of the listed countries?
  • How many MSLs do you have on staff in each country per therapeutic area supported?
  • What is the approximate annual total travel and entertainment (T&E) budget allocated to an MSL on average in each of the listed countries?
  • How many total staff are allocated to each of the listed MSL management and support roles in your region?
  • On average, what percentage of “peak MSL team size” are assigned to support a product at each phase of the typical product lifecycle?
  • In APAC, how effective is it to bring an MSL on board to support a product in each phase of the product lifecycle?

SAMPLE KEY FINDINGS
  • Travel & Entertainment Budget: Average annual budgets range from ~$9,500 in India and Japan, to $11,300 in China, up to nearly $19,000 in Australia. One Medical Director explained that by shrinking the territories of Australian MSLs and cross-training staff to support multiple TAs, the field team was able to efficiently engage a high number of KOLs and reduce travel costs.

METHODOLOGY

Best Practices, LLC engaged 125 Global Medical Affairs and Field Medical Excellence leaders from more than 40 leading pharma and biotech companies in this research through a benchmarking survey. In-depth interviews were conducted with 8 benchmark partners to gain further insights. The vast majority of study participants serve at the executive or director level. Together they provide a comprehensive view of field medical operations around the world, from a global, regional and local perspective.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Manufacturing; Consumer Products; Medical Device; Chemical; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbott; Alexion Pharmaceuticals; Allergopharma; Amgen; AstraZeneca; Bayer; Biogen; Bioventus; Boehringer Ingelheim; Celgene; Chiesi; Clovis Oncology; Dr Reddy's Laboratories; Eisai; Galderma; GE Healthcare; Gedeon Richter ; Gilead Sciences; Grifols; Ipsen; Janssen; Kiniksa Pharmaceuticals; Kyowa Kirin; Lupin; Merck; MSD; Novartis; Novelion Therapeutics; Pfizer; Rakuten Medical; Roche; Sandoz; Sanofi; Shire; Sunovion; Takeda Pharmaceuticals; UCB Pharma; Vertex Pharmaceuticals; Vifor Pharma; ViiV Healthcare

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.